The Valley Desk

Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)Published

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania, with Drexel University linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Arthritis & rheumatology (Hoboken, N.J.)
Published
Subject terms
Humans; Arthritis, Psoriatic; Tumor Necrosis Factor-alpha; Antirheumatic Agents; Treatment Outcome; Severity of Illness Index; Cross-Over Studies; Double-Blind Method; Adult; Middle Aged; Female; Male
PubMed ID
41670439
PubMed Central ID
PMC13430097
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal